{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:36:27Z","timestamp":1789403787379,"version":"build-2803163510"},"reference-count":137,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["aiche.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biotechnology Progress"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Severe acute respiratory syndrome coronavirus (SARS\u2010CoV), Middle East respiratory syndrome coronavirus (MERS\u2010CoV), and the current severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102) are the most impactful coronaviruses in human history, especially the latter, which brings revolutionary changes to human vaccinology. Due to its high infectivity, the virus spreads rapidly throughout the world and was declared a pandemic in March 2020. A vaccine would normally take more than 10\u2009years to be developed. As such, there is no vaccine available for SARS\u2010CoV and MERS\u2010CoV. Currently, 10 vaccines have been approved for emergency use by World Health Organization (WHO) against SARS\u2010CoV\u20102. Virus\u2010like particle (VLP)s are nanoparticles resembling the native virus but devoid of the viral genome. Due to their self\u2010adjuvanting properties, VLPs have been explored extensively for vaccine development. However, none of the approved vaccines against SARS\u2010CoV\u20102 was based on VLP and only 4% of the vaccine candidates in clinical trials were based on VLPs. In the current review, we focused on discussing the major advances in the development of VLP\u2010based vaccine candidates against the SARS\u2010CoV, MERS\u2010CoV, and SARS\u2010CoV\u20102, including those in clinical and pre\u2010clinical studies, to give a comprehensive overview of the VLP\u2010based vaccines against the coronaviruses.<\/jats:p>","DOI":"10.1002\/btpr.3292","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T23:23:38Z","timestamp":1659741818000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Development of virus\u2010like particles\u2010based vaccines against coronaviruses"],"prefix":"10.1002","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0842-6386","authenticated-orcid":false,"given":"Chean Yeah","family":"Yong","sequence":"first","affiliation":[{"name":"China\u2010ASEAN College of Marine Sciences Xiamen University Malaysia  Sepang Selangor Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie Pui Pui","family":"Liew","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Dietetics, Faculty of Medicine and Health Science Universiti Putra Malaysia  Serdang Selangor Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Kian","family":"Ong","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine and Health Science Universiti Putra Malaysia  Serdang Selangor Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8475-6291","authenticated-orcid":false,"given":"Chit Laa","family":"Poh","sequence":"additional","affiliation":[{"name":"Centre for Virus and Vaccine Research, School of Medical and Life Sciences Sunway University  Bandar Sunway Selangor Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00269-12"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.302.5653.2045"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1843.2003.00518.x"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1211721"},{"key":"e_1_2_11_6_1","unstructured":"WHO.MERS situation update February 2022. Accessed April 1 2022.http:\/\/www.emro.who.int\/health-topics\/mers-cov\/mers-outbreaks.html"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/zph.12171"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0450-0"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1519235113"},{"key":"e_1_2_11_10_1","unstructured":"WHO.Middle East respiratory syndrome coronavirus (MERS\u2010CoV)\u2014Saudi Arabia. 2021. Accessed September 2021.https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2021-DON333"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-019-0940-5"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.4178\/epih\/e2015033"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01280-15"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2018.031"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30251-8"},{"key":"e_1_2_11_16_1","unstructured":"WHO.Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Accessed August 18 2021.https:\/\/www.who.int\/publications\/m\/item\/summary-of-probable-sars-cases-with-onset-of-illness-from-1-november-2002-to-31-july-2003"},{"key":"e_1_2_11_17_1","unstructured":"Worldometer.COVID\u201019 coronavirus pandemic. 2021. Accessed December 2021.https:\/\/www.worldometers.info\/coronavirus\/."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507"},{"key":"e_1_2_11_19_1","unstructured":"Worldometer.COVID\u201019 coronavirus pandemic. 2022. Accessed April 2022.https:\/\/www.worldometers.info\/coronavirus\/"},{"key":"e_1_2_11_20_1","unstructured":"WHO.10 vaccines granted emergency use listing (EUL) by WHO. 2022. Accessed April 2022.https:\/\/covid19.trackvaccines.org\/agency\/who\/"},{"key":"e_1_2_11_21_1","unstructured":"KovacM.How COVID\u201019 is changing the approach for the vaccine development process. 2021. Accessed September 2021.https:\/\/www.ppd.com\/blog\/how-covid-19-is-changing-the-approach-for-the-vaccine-development-process\/."},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-2438-7_1"},{"key":"e_1_2_11_23_1","volume-title":"Structures and Functions of Coronavirus Replication\u2013Transcription Complexes and their Relevance for SARS\u2010CoV\u20102 Drug Design","author":"Malone B","year":"2021"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.REV120.013930"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0118-9"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13414-9"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1570"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2015.09.014"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2179-y"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104792"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.671633"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.037"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2017.03.015"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1134\/S0026893319030154"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/elps.201200257"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/life11010064"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007260070072"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa102"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-021-00806-7"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26320"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7020037"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-396547-9.00014-6"},{"key":"e_1_2_11_43_1","unstructured":"MallapatyS.India's DNA COVID vaccine is a world first \u2010 more are coming. 2021. Accessed July 2022.https:\/\/www.nature.com\/articles\/d41586-021-02385-x"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01100"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0006-8"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.08.007"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.03695-14"},{"key":"e_1_2_11_48_1","first-page":"2751","article-title":"Potential recombinant vaccine against influenza a virus based on M2e displayed on nodaviral capsid nanoparticles","volume":"10","author":"Yong CY","year":"2015","journal-title":"Int J Nanomedicine"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020275"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7030091"},{"key":"e_1_2_11_51_1","first-page":"1","article-title":"Virus\u2010like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice","volume":"7","author":"Yang M","year":"2017","journal-title":"Sci Rep"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jip.2011.05.004"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/plants10091828"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15080"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00267-3"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2015.01.005"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201800376"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20314-w"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9040395"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0285.2008.00746.x"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9040403"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1087"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/9783527626601.ch7"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01370-1"},{"key":"e_1_2_11_65_1","first-page":"2020.11.04.2022","article-title":"Phase 1 trial of a candidate recombinant virus\u2010like particle vaccine for COVID\u201019 disease produced in plants","author":"Ward BJ","year":"2020","journal-title":"medRxiv"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.02.008"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20251-8"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.18388\/abp.2014_1875"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.02.031"},{"key":"e_1_2_11_70_1","first-page":"269","article-title":"Dry aerosol vaccination against Newcastle disease. I. Safety and activity controls on chickens","volume":"33","author":"Fournier JM","year":"1976","journal-title":"Dev Biol Stand"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-017-0002-1"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-019-0167-6"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.8.881"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0955-3"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.01.003"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01679"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.04.016"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.111"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.11.092"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035421"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-0556-3-7"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.02.012"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-018-0064-8"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8475"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.12.019"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01093"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2019.10.007"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.04.082"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf1061"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201807616"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009064"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020073"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9080920"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78656-w"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00862"},{"key":"e_1_2_11_96_1","article-title":"Multi\u2010antigenic virus\u2010like particle of SARS CoV\u20102 produced in Saccharomyces cerevisiae as a vaccine candidate","author":"Arora K","year":"2020","journal-title":"bioRxiv"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2020.1807945"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10529-018-2516-5"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-009-2267-2"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12010-014-0814-5"},{"key":"e_1_2_11_101_1","unstructured":"CarlsonR.MERS vaccines 2022. Accessed July 2022.https:\/\/www.coronavirustoday.com\/mers-vaccines"},{"key":"e_1_2_11_102_1","unstructured":"WHO.COVID\u201019 vaccine tracker and landscape. 2021. Accessed December 2021.https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.051"},{"key":"e_1_2_11_104_1","unstructured":"Zimmer C Corum J Wee S\u2010L Kristoffersen M.Coronavirus vaccine tracker. 2022. Accessed August 2022. Available at:https:\/\/www.nyttimes.com\/interactive\/2020\/science\/coronavirus-vaccine-tracker.html"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.ijp_168_21"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02931"},{"key":"e_1_2_11_107_1","unstructured":"covidX. COVIVAXX. 2021. Accessed December 2021.https:\/\/www.covidx.eu\/covivaxx"},{"key":"e_1_2_11_108_1","article-title":"Interim report of a phase 2 randomized trial of a plant\u2010produced virus\u2010like particle vaccine for COVID\u201019 in healthy adults aged 18\u201364 and older adults aged 65 and older","author":"Gobeil P","year":"2021","journal-title":"medRxiv"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9090992"},{"key":"e_1_2_11_110_1","unstructured":"VBI.VBI vaccines announces collaboration with the National Research Council of Canada to develop pan\u2010coronavirus vaccine candidate targeting COVID\u201019 SARS and MERS. 2020.https:\/\/www.vbivaccines.com\/press-releases\/nrc-pan-coronavirus-vaccine-collaboration\/"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.07.034"},{"key":"e_1_2_11_112_1","unstructured":"Bavarian Nordic.Bavarian Nordic reports positive topline phase 2 results for its covid\u201019 vaccine candidate. 2021. Accessed February 2022.https:\/\/www.bavarian-nordic.com\/investor\/news\/news.aspx?news=6440"},{"key":"e_1_2_11_113_1","unstructured":"Expres2ion.Positive topline results reported for the phase II COVID\u201019 clinical trial with the ABNCoV2 vaccine. 2021.https:\/\/news.cision.com\/expres2ion\u2010biotechnologies\/r\/positive\u2010topline\u2010results\u2010reported\u2010for\u2010the\u2010phase\u2010ii\u2010covid\u201019\u2010clinical\u2010trial\u2010with\u2010the\u2010abncov2\u2010vaccine c3466288"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107763"},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10070788"},{"key":"e_1_2_11_116_1","unstructured":"MaxPlanck.Virus\u2010like particles as possible COVID\u201019 vaccine. 2020. Accessed December 2021.https:\/\/www.mpg.de\/15393185\/virus-like-particles-as-possible-covid-19-vaccine"},{"key":"e_1_2_11_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2016.12.076"},{"key":"e_1_2_11_118_1","unstructured":"IrsiCaixa.Project for the Development of Antibodies Drugs and a Vaccine against Coronavirus. 2020. Accessed September 9 2021.https:\/\/www.irsicaixa.es\/en\/news\/project-development-antibodies-drugs-and-vaccine-against-coronavirus"},{"key":"e_1_2_11_119_1","unstructured":"Navarrabiomed.SARS\u2010CoV\u20102 Biosecurity Vaccine Development Platforms. 2020. Accessed September 9 2021.http:\/\/eu\u2010isciii.es\/covidfundinspain\/sars\u2010cov\u20102\u2010biosecurity\u2010vaccine\u2010development\u2010platforms\/"},{"key":"e_1_2_11_120_1","unstructured":"Tampere University.Special COVID\u201019 funding for five projects at Tampere University. 2020. Accessed September 9 2021.https:\/\/www.tuni.fi\/en\/news\/special-covid-19-funding-five-projects-tampere-university"},{"key":"e_1_2_11_121_1","unstructured":"Saiba.Saiba AG selects AGC biologics to develop and produce COVID\u201019 vaccine. 2020. Accessed December 2021.https:\/\/www.saiba\u2010biotech.com\/2020\/06\/16\/saiba\u2010ag\u2010selects\u2010agc\u2010biologics\u2010to\u2010develop\u2010and\u2010produce\u2010covid\u201019\u2010vaccine\/"},{"key":"e_1_2_11_122_1","unstructured":"Saiba.Saiba AG shows encouraging preclinical data for its COVID\u201019 VLP\u2010based vaccine. 2020. Accessed December 2021.https:\/\/www.saiba-biotech.com\/2020\/03\/25\/saiba-ag-shows-encouraging-preclinical-data-for-its-covid-19-vlp-based-vaccine\/"},{"key":"e_1_2_11_123_1","unstructured":"Saiba.Saiba AG focuses on a future COVID\u201019 vaccine with advantages over first to market vaccine candidates. 2020. Accessed December 2021.https:\/\/www.saiba-biotech.com\/2020\/09\/16\/saiba-ag-focuses-on-a-future-covid-19-vaccine-with-advantages-over-first-to-market-vaccine-candidates\/"},{"key":"e_1_2_11_124_1","unstructured":"BernaBiotechPharmaGmbH.Corona vaccine COVID\u201019.2021. Accessed September 2021.https:\/\/www.berna-swiss.com\/covid-19-1"},{"key":"e_1_2_11_125_1","unstructured":"NessiE.Berna Biotech Pharma and Swiss Biotech Center to develop second\u2010generation COVID\u201019 vaccine. 2021. Accessed December 2021.https:\/\/www.s-ge.com\/en\/article\/news\/20212-lifesciences-swissbiotechcenter"},{"key":"e_1_2_11_126_1","unstructured":"Innovations S.ASU is actively engaged in the fight against COVID\u201019. 2021. Accessed December 2021.https:\/\/www.skysonginnovations.com\/stories\/asu-covid-technologies\/"},{"key":"e_1_2_11_127_1","first-page":"1","article-title":"Vaccine efficacy in mutant SARS\u2010CoV\u20102 variants","volume":"4","author":"Kandikattu HK","year":"2021","journal-title":"Int J Cell Biol Physiol"},{"key":"e_1_2_11_128_1","unstructured":"University\u2010of\u2010Bristol.New vaccine platform used to develop COVID\u201019 candidates. 2020. Accessed September 9 2021.http:\/\/www.bristol.ac.uk\/news\/2020\/april\/covid-19-vaccine-platform.html"},{"key":"e_1_2_11_129_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.55"},{"key":"e_1_2_11_130_1","unstructured":"LansdowneLE.Developing temperature\u2010stable ADDomer vaccines for untreatable diseases. 2021. Accessed December 2021.https:\/\/www.technologynetworks.com\/biopharma\/blog\/developing-temperature-stable-addomer-vaccines-for-untreatable-diseases-356788"},{"key":"e_1_2_11_131_1","unstructured":"3PBiopharmaceuticals.Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS\u2010COV\u20102. 2021. December 2021.https:\/\/3pbio.com\/wp-content\/uploads\/2021\/11\/PressRelease-Osivax-Covid19-2021r.pdf"},{"key":"e_1_2_11_132_1","unstructured":"SilvaDD.University of Manitoba a treatment for COVID\u201019 will be found reassures UM virologist. 2020. Accessed September 9 2021.https:\/\/news.umanitoba.ca\/a\u2010treatment\u2010for\u2010covid\u201019\u2010will\u2010be\u2010found\u2010reassures\u2010um\u2010virologist\/"},{"key":"e_1_2_11_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104759"},{"key":"e_1_2_11_134_1","unstructured":"ARTES.ARTES joins global combat against corona. 2020. Accessed December 2021.https:\/\/artes-biotechnology.biz\/artes-joins-global-combat-against-corona\/"},{"key":"e_1_2_11_135_1","unstructured":"ARTES.SplitCore\u2014the latest milestone in ARTES\u00b4 vaccine development offer. 2020. Accessed December 2021http:\/\/artes\u2010biotechnology.biz\/splitcore\u2010the\u2010latest\u2010milestone\u2010in\u2010artes\u2010vaccine\u2010development\u2010offer\/"},{"key":"e_1_2_11_136_1","unstructured":"ARTES.METAVAX\u00ae. 2013. Accessed December 2021.https:\/\/artes-biotechnology.biz\/metavax-3\/"},{"key":"e_1_2_11_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmni.2020.100786"},{"key":"e_1_2_11_138_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10529-021-03211-0"}],"container-title":["Biotechnology Progress"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/btpr.3292","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/btpr.3292","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aiche.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/btpr.3292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T08:50:24Z","timestamp":1761641424000},"score":1,"resource":{"primary":{"URL":"https:\/\/aiche.onlinelibrary.wiley.com\/doi\/10.1002\/btpr.3292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":137,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/btpr.3292"],"URL":"https:\/\/doi.org\/10.1002\/btpr.3292","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/BTPR.3292\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BTPR.3292\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BTPR.3292\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BTPR.3292\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BTPR.3292\/v1\/review1","asserted-by":"object"}]},"ISSN":["8756-7938","1520-6033"],"issn-type":[{"value":"8756-7938","type":"print"},{"value":"1520-6033","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"assertion":[{"value":"2022-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e3292"}}